Background {#Sec1}
==========

Endometrial cancer (EC) is one of the three major gynecological malignancies and fifth most common cancer among women (4.8% of female cancer cases) in the United States \[[@CR1]\]. It is expected that 61,880 new cases will be diagnosed in 2019 (7% of all female cancer cases) and 12,160 deaths (4% of all female cancer deaths). In the past ten years, with the irregular use of hormones and changes in people's living environment and lifestyle, the prevalence and mortality of endometrial cancer in China and abroad have been increasing annually \[[@CR2]\]. Although most patients are diagnosed early, approximately 28% of patients are diagnosed with advanced disease. However, patients with the same degree of progression can show different prognoses and treatment responses. Therefore, effective EC biomarkers must be discovered for assessing prognosis and identifying potentially patients at a high risk of EC.

Numerous biomarkers for EC have been identified, such as the SIX1 and HER-2 genes \[[@CR3], [@CR4]\]. With advancements in high-throughput sequencing, researchers have established various patient genome databases to enable a more systematic understanding of genomic changes. Through database mining, we identified thousands of biomarkers that may be associated with the prognosis of patients with tumors \[[@CR5], [@CR6]\]. However, the predictive ability of single-gene biomarkers remains insufficient. Studies have shown that the evaluation of genetic traits, which involve multiple genes, may improve prognosis prediction \[[@CR7], [@CR8]\]. Multigenic prognostic features from primary tumor biopsy can guide more specific treatment strategies. Recent studies have explored the effects of multiple-gene signature on EC for assessing prognosis and identifying potentially patients at a high risk of EC \[[@CR9], [@CR10]\].

In this study, genes were selected by performing gene set enrichment analysis (GSEA). To identify biomarkers, differential analysis typically involves comparison of the expression differences between groups and focuses on genes whose expression levels are significantly regulated. However, this method can easily exclude genes that do not show obvious expression differences but may provide important biological information or exhibit biological significance. As an emerging computational method, GSEA does not require a clear differential gene threshold or extensive experience to test the overall expression of several genes. It reveals general trends in the data. Therefore, this approach improves the statistical analysis between biological expression and biological significance \[[@CR11]\].

Accordingly, in the present study, we aimed to explore data from The Cancer Genome Atlas (TCGA) to identify a new genetic signature for predicting the prognosis of EC. To this end, we used mRNA expression data from TCGA to map the marker genome of 548 patients with EC. We identified 119 mRNAs significantly related to glycolysis and developed a nine-gene risk profile for effectively predicting patient outcomes. Interestingly, the risk factors associated with glycolysis can be used assess prognosis of high-risk patients independently. A novel cell glycolysis-related gene signature was identified and validated.

Methods {#Sec2}
=======

Clinical information and mRNA expression data set of patients {#Sec3}
-------------------------------------------------------------

We extracted clinical data and the mRNA expression profiles of patients with endometrial cancer from TCGA (<https://cancergenome.nih.gov/>) \[[@CR12]\]. The study included clinical information from 548 patients and enrolled matching age, stage, grade, radiation therapy, residual tumor, histological type, diabetes, new tumor events, and hypertension (Table [1](#Tab1){ref-type="table"}).Table 1Clinical pathological parameters of patients with Endometrioid cancer in this studyClinical pathological parametersN%Dead numberAge ≥ 6623643.247 \< 6631056.840Neoplasm cancer status With tumor7915.548 Tumor free4318.535Residual tumor R037694.547 R1225.55Stage I34162.229 II--IV20737.858New event No48588.554 Yes6311.533Grade G19918.42 G212222.714 G331658.665Histological type Endometrioid adenocarcinoma4117546 Serous adenocarcinoma/mixed1372541Radiation therapy No51794.384 Yes315.73Diabetes No53397.386 Yes152.71Hypertension No51794.385 Yes315.72

Gene set enrichment analysis {#Sec4}
----------------------------

We performed GSEA (<http://www.broadinstitute.org/gsea/index.jsp>) to determine if the identified gene sets were significantly different between the EC and normal groups. Next, we analyzed the expression levels of 24,991 mRNAs in EC samples and in adjacent noncancerous tissues. Finally, we determined functions for subsequent analysis by using normalized p values (p \< 0.05).

Data processing and risk-parameter calculation {#Sec5}
----------------------------------------------

Log2 transformation was used to normalize each mRNA from among the expression profiles. Univariate Cox regression analysis was used to identify genes associated with overall survival (OS), which were then subjected to multivariable Cox regression to confirm the genes related to prognosis and obtain the coefficients. The selected mRNAs were then divided into the risky (hazard ratio, HR \> 1) type and protective (0 \< HR \< 1) type. By linearly combining the expression values of filtered genes weighted by their coefficients, we constructed a risk-parameter formula as follows: Risk parameter = ∑ (βn × expression of gene n). Using the median risk parameter as a cut-off, the 548 patients were divided into high‐risk and low‐risk subgroups.

Specimens and patients of quantitative real-time (qRT)-PCR {#Sec6}
----------------------------------------------------------

A total of 20 EC tissues and 20 normal endometrial tissues were obtained from patients at the Department of Gynecology and Obstetrics, Shengjing Hospital of China Medical University, China. Normal tissues were obtained from patients who underwent hysterectomy for endometrial-irrelevant diseases. All patients provided informed consent, and this study was approved by the Ethics Committee of Shengjing Hospital of China Medical University. Histological diagnosis and grade were assessed by experienced pathologists in accordance with the FIGO 2009. No patient was administered systemic treatment preoperatively.

RNA extraction and qRT-PCR {#Sec7}
--------------------------

Total RNA was extracted from tissues using TRIzol reagent (Vazyme, Nanjing, China). PrimeScript RT-polymerase (Vazyme) was used to reverse-transcribe cDNAs corresponding to the mRNAs of interest. qRT-PCR was performed using SYBR-Green Premix (Vazyme) with specific PCR primers (Sangon Biotech Co., Ltd, Shanghai, China). Glyceraldehyde-3-phosphate dehydrogenase was used as an internal control. The 2^−ΔΔCt^ method was used to calculate fold-changes. Primer sequences are listed in Additional file [1](#MOESM1){ref-type="media"}: Table S1.

Statistical analysis {#Sec8}
--------------------

We used Kaplan--Meier survival curves and the log‐rank method to estimate the significance of the risk parameter. We performed multivariate Cox analysis and data stratification analysis to test whether the risk parameter was independent of the clinical features, including age, grade, stage, new event, residual tumor, and neoplasm cancer status, which were used as covariates. A p \< 0.05 was considered as statistically significant. Statistical analyses were performed using GraphPad Prism7 software (GraphPad, Inc., La Jolla, CA, USA) and SPSS 20.0 software (SPSS, Inc., Chicago, IL, USA).

Results {#Sec9}
=======

Initial screening of genes by GSEA {#Sec10}
----------------------------------

We obtained the clinical features of 548 patients with EC, along with an expression data set for 24,991 mRNAs from TCGA database. We performed GSEA to determine if the identified gene sets were significantly different between EC tissues and endometrium tissues. We validated 26 gene sets that were upregulated in EC. Ten gene sets, G2 M checkpoints, MYC targets V1, glycolysis, MYC targets V2, MTORC1 signaling, oxidative phosphorylation, DNA repair, unfolded protein response, E2F targets, and UV response, were significantly enriched (Table [2](#Tab2){ref-type="table"}, Fig. [1](#Fig1){ref-type="fig"}). We then filtered the top‐ranking function, glycolysis (p = 0.000), among 119 genes for subsequent analysis.Table 2Gene sets enriched in Endometrial cancer (548 samples)GS follow link to MSigDBSIZEESNOM *p*‐valueRank at MAXE2F targets1990.74902428G2M checkpoint1980.67403343MTORC1 signaling1970.67304792MYC targets V11990.65704404MYC targets V2580.76804140Glycolysis1970.58706922Oxidative phosphorylation1990.57805082DNA repair1420.53105276Unfolded protein response1090.48304590UV response up1550.45504007 Fig. 1Enrichment plots of nine gene sets which had significant difference between noncancerous tissues and EC tissues by performing GSEA

Identification of survival-associating glycolysis‐related mRNAs {#Sec11}
---------------------------------------------------------------

First, we performed univariate Cox regression analysis of 119 genes for preliminary screening and obtained 21 genes (p \< 0.05). Next, multivariate Cox regression analysis was performed to further examine the association between the 21 mRNA expression profiles and patient survival, and the stepwise elimination method was used to identify the most significant mRNAs combinations. Nine mRNAs (*CLDN9*, *B4GALT1*, *GMPPB*, *B4GALT4*, *AK4*, *CHST6*, *PC*, *GPC1*, and *SRD5A3*) were verified, as shown in Table [3](#Tab3){ref-type="table"}, and six of the nine genes (*CLDN9*, *B4GALT1*, *GMPPB*, *AK4*, *PC*, and *SRD5A3*) were validated as independent prognostic markers of EC. The filtered mRNAs were divided into the risky type (*CLDN9*, *AK4*, *PC*, *GPC1*, and *SRD5A3*), with HR \> 1 associated with poorer survival and the protective type (*B4GALT1*, *GMPPB*, *B4GALT4*, and *CHST6*), with HR \< 1 associated with better survival (Table [3](#Tab3){ref-type="table"}).Table 3The detailed information of nine prognostic mRNAs significantly associated with overall survival in patients with endometrial cancermRNAEnsemble IDLocationΒ (Cox)HRpCLDN9ENSG00000213937chr 16: 3,012,923--3,014,5050.10591.11170.0258B4GALT1ENSG00000086062chr 9: 33,104,082--33,167,356− 0.25040.77850.0203GMPPBENSG00000173540chr 3: 49,716,844--49,723,951− 0.43460.64750.0134B4GALT4ENSG00000121578chr 3: 119,211,732--119,240,946− 0.30410.73780.0839AK4ENSG00000162433chr 1: 65,147,549--65,232,1450.31811.37460.0015CHST6ENSG00000183196chr 16: 75,472,052--75,495,445− 0.11910.88780.0665PCENSG00000173599chr 11: 66,848,417--66,958,4390.3281.38820.0233GPC1ENSG00000063660chr 2: 240,435,663--240,468,0760.20561.22820.1022SRD5A3ENSG00000128039chr 4: 55,346,242--55,373,1000.23451.26430.05

We then assessed the alterations in nine filtered genes by analyzing 548 EC samples in the cBioPortal database (<http://cbioportal.org>) \[[@CR13]\]. The results showed that the queried genes were altered in 98 (18.3%) of the sequenced cases. The PC gene included ten amplification samples, 2 deep deletion samples, 7 missense mutations samples, and one sample with an in-frame mutation. The CLDN9 gene was altered in 2% of cases, showing various changes. The CHST6 gene was altered in 2.8% of cases, and the B4GALT1 and B4GALT4 genes were altered in 2.4% and 1.8% of cases, respectively (Fig. [2](#Fig2){ref-type="fig"}a).Fig. 2Identification of mRNAs related to patients' survival. **a** Selected genes' alteration in 548 clinical samples. **b** Selected genes' specific alteration in different pathological types of EC. **c** Different expression of nine selected genes

The specific alterations in the selected genes were significant in specific cancer types. In EC, 3.88% of changes were mutations, 7.17% were amplifications, 2.67% were deep deletions, and 0.16% were multiple alterations. In endometrioid adenocarcinoma, the only alteration was amplification (12.76% of patients). In mixed serous and endometrioid cases, the most eminent alteration was mutation (Fig. [2](#Fig2){ref-type="fig"}b).

Comparison of the expression differences of 9 genes between adjacent normal tissues and EC tissues was also performed. We found that the expression levels of the nine genes were significantly up- or downregulated in EC tissues (Fig. [2](#Fig2){ref-type="fig"}c).

Validation of TCGA expression results using qRT-PCR {#Sec12}
---------------------------------------------------

We examined the expression of 9 mRNAs by qRT-PCR in 20 EC tissues and 20 normal endometrial tissues. We applied the unpaired *t* test to assess the differences between the two groups. The results showed that *CLDN9*, *AK4*, *PC*, *GPC1*, and *SRD5A3* were upregulated in EC tissues compared to in normal endometrium tissues, whereas *B4GALT1*, *GMPPB*, *B4GALT4*, and *CHST6* were downregulated in tumor tissues (Fig. [3](#Fig3){ref-type="fig"}). The mRNA expression results of qRT-PCR validation in 20 patients with EC were consistent with the bioinformatics results, which showed that the bioinformatics analysis was precise and gave significant results.Fig. 3Expression of nine mRNAs in endometrial cancer tissues and normal tissues. **a** CLDN9, **b** B4GALT1, **c** GMPPB, **d** B4GALT4, **e** AK4, **f** CHST6, **g** PC, **h** GPC1, **i** SRD5A3

Construction of a nine‐mRNA signature to predict patient outcomes {#Sec13}
-----------------------------------------------------------------

By linearly combining the expression values of selected genes weighted by their coefficients derived from multivariate Cox regression analysis, we established the following prognostic risk-parameter formula. Risk parameter = 0.1059 × expression of *CLDN9* + 0.3181 × expression of *AK4* + 0.328 × expression of *PC* + 0.2056 × expression of *GPC1* + 0.2345 × expression of *SRD5A3* − 0.2504 × expression of *B4GALT1 *− 0.3041 × expression of *B4GALT4* − 0.4346 × expression of *GMPPB* − 0.1191 × expression of *CHST6*. We calculated parameters and assigned one risk parameter to each patient. We then ranked the patients in ascending order by the parameter and divided the patients into high-risk and low-risk subgroups using the median (Fig. [4](#Fig4){ref-type="fig"}a). The survival time of each patient is shown in Fig. [4](#Fig4){ref-type="fig"}b. Patients in the high‐risk parameter group showed poorer survival, whereas patients with the low‐risk parameter had lower mortality rates. Additionally, a heatmap displayed the expression profiles of nine mRNAs (Fig. [4](#Fig4){ref-type="fig"}c). Compared to the low-risk group, the expression level of risky-type mRNA (*CLDN9*, *AK4*, *PC*, *GPC1*, and *SRD5A3*) was higher in the high-risk group. In contrast, the expression level of protective-type mRNA (*CLDN9*, *AK4*, *PC*, *GPC1*, and *SRD5A3*) in the high-risk group was lower than that in the low-risk group. The expression levels of the nine genes in the high and low risk groups are shown in Additional file [2](#MOESM2){ref-type="media"}: Figure S1.Fig. 4The nine‐mRNA signature associated with risk parameter predicts OS in patients with endometrial cancer. **a** mRNA risk parameter distribution in each patient. **b** Survival days of EC patients in ascending order of risk parameters. **c** A heatmap of nine genes' expression profile. **d** GO analysis and KEGG analysis of nine differentially expressed mRNAs

We performed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses of differentially expressed mRNAs, including KEGG pathway enrichment analysis and GO functional annotation analysis of the 9 differentially expressed genes in the high- and low-risk groups (Fig. [4](#Fig4){ref-type="fig"}d). KEGG pathway enrichment analysis showed that the differentially expressed genes were involved in multiple signaling pathways and enriched in neuroactive ligand-receptor interaction, protein digestion and absorption, regulation of lipolysis in adipocytes, and another 12 pathways. The two groups of differentially expressed genes were annotated with GO functions and analyzed for their significant functions. The results revealed 15 GO items in the significantly enriched molecular function category, including ion channel activity, substance-specific channel activity, and passive transmembrane transporter activity, among which passive transmembrane transporter activity was the most significantly enriched GO term.

Risk parameter derived from nine-mRNA signature is an independent prognostic indicator {#Sec14}
--------------------------------------------------------------------------------------

We compared the prognostic value of risk parameters with clinical pathology parameters by univariate and multivariate analyses (Table [1](#Tab1){ref-type="table"}). Samples with well-established clinical data were selected. The median age of the 546 patients with EC was 66 years. Among the 548 patients, 63 (11.5%) had a new event during the follow‐up, 459 (75%) had endometrioid adenocarcinoma, and 31 (5.7%) suffered from hypertension. Among the 398 patients, 22 (5.5%) had residual tumors, and 99 (18.4%) had grade 1 tumors. Among 537 patients, 99(18.4%)had grade 1 tumors, 122 (22.7%) had grade 2 tumors, and the remaining 316 (58.6%) had grade 3 tumors. Furthermore, among the 548 patients with EC, 341 (62.2%) patients had stage I disease, and the remaining 207 (37.8) patients had stage II--IV disease. From the data set above, we identified the risk parameter, stage, grade, neoplasm cancer status, and new tumor event as independent prognostic indicators, as these factors showed significant differences in both univariate and multivariate analyses (Table [4](#Tab4){ref-type="table"}). Notably, the risk parameters showed significant prognostic values with p \< 0.05 (HR = 1.783).Table 4Univariable and multivariable analyses for each clinical featureClinical featureNumberUnivariate analysisMultivariate analysisHR95%CI of HRP valueHR95%CI of HRP valueRisk parameter(High-risk/Low-risk)274/2743.5292.186--5.699**\< **0.0012.4821.832--4.2580.038Age (≥ 66/\< 66)236/3101.8171.180--2.7980.0071.4820.820--2.6780.192Stage (I/II--IV)341/2073.5772.288--5.594**\< **0.0011.6581.010--2.7210.046Grade (G1/G2--3)99/43812.8113.148--52.128**\< **0.0017.8261.052--58.2050.044Residual tumor (yes/no)22/3762.8841.778--4.678**\< **0.0010.7450.402--1.3800.349New tumor event (yes/no)63/4854.9313.189--7.625**\< **0.0012.7731.604--4.798**\< **0.001Neoplasm cancer status(with tumor/tumor free)79/4316.4044.140--9.908**\< **0.0013.5091.895--6.498**\< **0.001Histological type (endometrioid adenocarcinoma/others)411/1371.8541.186--2.8960.0070.7080.406--1.2370.225

Verification of nine‐mRNA signature for prognosis prediction by K--M survival estimates {#Sec15}
---------------------------------------------------------------------------------------

K--M survival estimates and the log‐rank test revealed that patients in the high-risk group had a poor prognosis (Fig. [5](#Fig5){ref-type="fig"}a). Univariate Cox regression analysis of OS revealed several clinicopathological parameters which were predictive of EC survival, including age, grade, stage, history of cancer, residual tumor, tumor recurrence (new events), and histological type. We then used the Kaplan--Meier survival estimates to validate the above conclusions, which showed consistent results, Patients older than 66 years, with tumor grade G2--3, disease stage II--IV, histological type of serous adenocarcinoma or mixed serous/endometrioid, and suffering from tumor recurrence (new events) and residual tumors were associated with poor prognosis (Fig. [5](#Fig5){ref-type="fig"}b, c). These results further confirmed the reliability of the analysis.Fig. 5Kaplan--Meier survival analysis for EC patients in TCGA data set. **a** K--M survival curve for EC patients with high/low risk. **b** Clinical features including age, grade, stage, neoplasm cancer status, residual tumor and new event predict patients survival. **c** histological type predict patients survival

After further data mining and stratified analysis, the survival curves were not affected by stage (stage I or stage II--IV), and the nine-mRNA signature was validated as a reliable prognostic indicator for patients with EC. Patients in the high-risk group showed a poor prognosis (Fig. [6](#Fig6){ref-type="fig"}b). Similarly, despite the tumor grade, neoplasm cancer status, and tumor recurrence, the risk parameter based on the nine‐mRNA signature could be used to predict the prognosis of patients with EC (Fig. [6](#Fig6){ref-type="fig"}c--e). However, when we stratified patients with EC into two subgroups according to age (\> 66 or ≤ 66 years), the risk parameter could no longer be independently used as an prognostic indicator for the subgroup of age \< 66 years (Fig. [6](#Fig6){ref-type="fig"}a), indicating that the risk parameter is affected by the age of patients with EC; this point requires further exploration.Fig. 6Kaplan--Meier curves for prognostic value of risk parameter signature for the patients divided by each clinical feature. **a** Age, **b** stage, **c** grade, **d** Person neoplasm cancer status, **e** new event

Discussion {#Sec16}
==========

Recent studies showed that clinicopathological features such as age and metastatic diagnosis are not sufficient to precisely predict the outcome of patients with cancer. Thus, an increasing number of mRNAs have been identified as biomarkers of tumor progression or prognosis, and the clinical significance of the biomarkers has been evaluated \[[@CR14]\]. For example, Nadaraja et al. \[[@CR15]\] confirmed that low expression of ARAP1 is an independent prognostic biomarker of shorter progression-free survival in older patients with ovarian high-grade serous adenocarcinoma being administered first-line platinum-based antineoplastic therapy. Similarly, multivariate Cox proportional hazards regression model analysis was used to verified that patients with cervical cancer who had high tumor protein p73 expression had better outcomes, and thus this protein was considered as a prognostic indicator in patients with cervical cancer \[[@CR16]\]. However, these biomarkers were still not sufficient for independently predicting patient prognosis. Particularly, single gene expression levels can be affected by multiple factors, preventing these markers from being used as reliable and independent prognosis indicators. Thus, a statistical model comprised of genetic markers for multiple related genes, combined with the predictive effect of each constituent gene, was used to improve prediction. The model is significantly more accurate than using single biomarkers in assessing the prognosis of patients with tumors \[[@CR17], [@CR18]\], leading to widespread use of the model.

The rapid development of high-throughput genetic sequencing technology has established a foundation for large biological data research \[[@CR19]\]. Large amounts of genomic data were extracted from individual specimens to identify new diagnostic, prognostic, or pharmacological biomarkers \[[@CR20]\]. In recent studies, a new prognostic signature was constructed by using microarray and RNA-sequencing data for gene expression levels or mutations. A Cox proportional hazards regression model was used for identification and verification \[[@CR21], [@CR22]\]. In the current study, we identified 10 functions showing significant differences in GSEA. As described above, rather than wide-range exploration, we selected the top‐ranking function to filter genes related to patient survival prediction. Univariate and multivariate Cox regression analyses were performed to determine the prognostic value of the combination of nine genes for patients with EC. This selected risk profile may be a more targeted and powerful prognostic assessment for predicting positive clinical outcomes and may be a more effective classification tool for patients with EC compared to other known prognostic assessment markers.

In this study, bioinformatics methods were used to explore the characteristics of mRNA risk factors and their clinical significance, and a new method for mining of potential prognostic markers was explored. This study y complements the previous understanding of EC and provides a foundation for future EC research. We used the EC dataset in TCGA to collect glycolysis-related genes and compare data from normal and EC tissues. Kaplan--Meier survival estimates revealed that patients with low-risk parameters had a better prognosis. The detection and calculation of risk parameter in EC patients have important clinical implications. However, because of the lack of patient metastasis and recurrence information in TCGA database, we could only use OS to assess patient prognosis, which is one limitation of our research. Additionally, in stratified analysis, the risk parameter could predict the prognosis of patients with EC in all subgroups except for the subgroup of age \< 66 years. The reason for this difference is unclear requires further examination.

In addition, the nine-gene signature and same analysis method in liver cancer and colon cancer were used to obtain and verify the corresponding risk parameter (Additional file [3](#MOESM3){ref-type="media"}: Figure S2; Additional file [4](#MOESM4){ref-type="media"}: Figure S3). The results showed that the risk parameter based on the nine genes is not an independent prognostic indicator for liver cancer and colon cancer, confirming that the nine-gene signature is particularly important in EC.

Tumors are characterized by uncontrolled cell proliferation, which not only eliminates control of the cell cycle but also promotes cellular energy metabolism and finally leads to tumor cell growth and differentiation. Cellular energy is mainly derived from sugar metabolism, and most energy is supplied by ATP. In the 1920s, the German biologist Otto Warburg discovered abnormalities in energy metabolism in hepatoma cells. Although oxygen is present, tumor cells mainly rely on glycolysis for metabolism and consume large amounts of glucose accompanied by lactic acid production. This phenomenon of abnormal glucose metabolism was named as aerobic glycolysis or the Warburg effect \[[@CR23]\]. Studies have shown that tumor cells can precisely regulate ATP synthesis by regulating substrate uptake and enzymes related to glycolysis, enabling them to adapt to the nutrient microenvironment, meet the energy and nutrient requirements for malignant proliferation, rapidly proliferate. Moreover, cancer metabolic reprogramming, which is closely associated with the Warburg effect, plays an important role in maintaining the interaction between oxygen-sensing transcription factors and the nutrient-sensing signal pathway \[[@CR24]\]. This indicates that aerobic glycolysis uses a complicated mechanism of action. Tumor cell proliferation proceeds at a pace exceeding cellular energy supply, and thus excessive consumption of oxygen and nutrients by the cells can cause the tumor microenvironment to be hypoxic, low in sugar, and acidic, which is more pronounced in solid tumors \[[@CR25]\]. Although not all tumors exhibit the Warburg effect, cellular energy abnormalities are widely recognized as one of the characteristics of tumor cells. After more than 90 years of continuous exploration and research, the Warburg effect has been found to occur in many malignancies, such as lung cancer, breast cancer, colon cancer, and gastric cancer. Recent studies showed that aerobic glycolysis plays an important role in EC occurrence and development. Metabolic profiling of EC cells revealed higher rates of glycolysis and lower glucose oxidation, and tumor cells may rely on GLUT6-mediated glucose transport and glycolytic--lipogenic metabolism for survival \[[@CR26]\]. Highly differentiated EC showed significantly lower GLUT1 and GLUT3 expression than poorly differentiated tumors \[[@CR27]\]. Several studies have predicted the survival of patients with EC using genes associated with cellular glycolysis. For example, high mobility group protein 1 suppression effectively inhibits the development and progression of EC \[[@CR28]\]. The expression of lactate dehydrogenase 5 in EC is an independent prognostic indicator strongly associated with poor prognosis \[[@CR29]\]. However, glycolysis-related gene markers for predicting EC prognosis have not been established. Using bioinformatics methods, we determined the genetic characteristics associated with cellular aerobic glycolysis (*CLDN9*, *B4GALT1*, *GMPPB*, *B4GALT4*, *AK4*, *CHST6*, *PC*, *GPC1*, and *SRD5A3*) and demonstrated their prognostic value in EC.

Conclusion {#Sec17}
==========

We developed a nine-gene risk profile associated with cellular glycolysis which predicts the prognosis of patients with EC, with a higher risk parameter indicating poorer prognosis. The signature can be a used as a classification tool in clinical practice. These findings provide insight into the mechanisms of cellular glycolysis and identification of patients with poor prognosis in EC.
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**Additional file 1: Table S1.** Primer sequence. **Additional file 2: Figure S1.** Expression of nine genes in high and low risk groups (\* represents for p \< 0.01, \*\* represent for p \< 0.001, \*\*\*\* represent for p \< 0.00001). **Additional file 3: Figure S2.** (a) The Kaplan--Meier curve for patients divided into high risk and low risk in liver cancer. 45(b) Different expression of nine selected genes in liver cancer. **Additional file 4: Figure S3.** a) The Kaplan--Meier curve for patients divided into high risk and low risk in colon cancer. (b) Different expression of nine selected genes in colon cancer.
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